Retatrutide vs tirzepatide: what the Phase 3 data shows

Triple agonist vs dual agonist: the mechanism gap

Tirzepatide hits two receptors: GLP-1 and GIP. GLP-1 slows gastric emptying and suppresses appetite. GIP amplifies insulin response and, at tirzepatide doses, appears to blunt the nausea that GLP-1 agonism can cause. The combination produces more weight loss than either receptor alone. That is why tirzepatide outperformed semaglutide in every head-to-head comparison.

Retatrutide adds a third receptor: glucagon. Glucagon receptors sit mainly in the liver. Activating them raises resting energy expenditure by telling the liver to burn fatty acids directly. The body burns more fuel at baseline, even while sedentary. That mechanism does not exist in tirzepatide or semaglutide. It also does not exist in survodutide, which pairs GLP-1 with glucagon but omits the GIP receptor.

Eli Lilly combined all three in retatrutide. The hypothesis was that hitting energy intake (GLP-1), insulin signaling (GIP), and energy expenditure (glucagon) together would outperform any two. TRIUMPH-1 confirmed it.

Retatrutide vs tirzepatide weight loss: the Phase 3 numbers

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight without diabetes. At 80 weeks on the 12mg dose, mean weight loss was 28.3%. In the subgroup with BMI of 35 or above who continued to 104 weeks, the number reached 30.3%. These are the largest Phase 3 results ever recorded for an obesity drug.

SURMOUNT-1 enrolled 2,539 adults under similar conditions. At 72 weeks on the 15mg dose, mean weight loss was 20.9%. On the 10mg dose, 19.5%. These are the numbers the FDA reviewed for Zepbound's obesity approval.

The gap between 28.3% and 20.9% is 7.4 percentage points. At 250 lbs, that is 18.5 more pounds lost on retatrutide. At 300 lbs, about 22 more pounds. That is not a rounding difference. It is a clinically meaningful gap, and it is the largest recorded between any two Phase 3 obesity drugs.

For context: semaglutide at 14.9% was considered a breakthrough when STEP 1 reported. Tirzepatide at 20.9% was the largest number anyone had seen in a drug trial. Retatrutide at 28.3% is in a different category entirely.

Side effects: the price of a stronger signal

More receptor activation means more side effect exposure. Retatrutide's GI adverse event rates are higher than tirzepatide's at comparable dose escalation speeds. Nausea, vomiting, and diarrhea occur more frequently, and the dose titration schedule in TRIUMPH-1 was longer than SURMOUNT-1 to manage this.

Glucagon receptor activation also causes a mild but consistent elevation in resting heart rate. TRIUMPH-1 reported this, and it was present at higher rates than in tirzepatide trials. It did not rise to a safety-stopping signal, but it is a difference worth knowing about for people with existing cardiac conditions.

Tirzepatide, by contrast, has four years of real-world data and a well-characterized safety profile. The GI side effects are real but manageable at current titration schedules. The cardiac signal is minimal. For most people starting GLP-1 therapy today, the side effect profile is a point in tirzepatide's favor.

Diabetes: retatrutide catching up to tirzepatide

Tirzepatide is approved for type 2 diabetes under the brand Mounjaro, with an HbA1c reduction of 2.1 percentage points in SURPASS-2. It has a robust diabetes dataset spanning five Phase 3 SURPASS trials, a cardiovascular outcomes trial, and an established prescribing history in millions of patients with T2D.

Retatrutide cleared its Phase 3 diabetes trial in March 2026. The TRIUMPH-2 data, reported by Eli Lilly, showed the drug performing in line with TRIUMPH-1 on metabolic markers including HbA1c. This removes a risk that had hung over the program: the possibility that the glucagon receptor would impair glycemic control at high doses. It did not. The diabetes data clears the path for a broad NDA filing.

For now, tirzepatide remains the better-established choice for people managing both obesity and type 2 diabetes. The retatrutide diabetes dataset exists but is newer and less deeply studied.

Availability: tirzepatide today, retatrutide in 2027 at the earliest

Tirzepatide is FDA-approved for both obesity (Zepbound) and type 2 diabetes (Mounjaro). It is available through telehealth programs, endocrinologists, and primary care providers. Compounded tirzepatide has faced regulatory restriction since early 2026, but brand access through telehealth and standard prescribing remains open.

Retatrutide is not FDA-approved. Eli Lilly has stated clearly that the only legal way to access it is through an active clinical trial. The company plans to file an NDA in Q4 2026. Standard FDA review takes 10 to 12 months, putting a decision in late 2027 under the most optimistic scenario. Delays for labeling, manufacturing inspection, or supplementary safety review would push that further. Vendors advertising compounded retatrutide online are selling something that is not retatrutide. The FDA has issued warnings about gray-market versions.

The gap between the two drugs on paper is large. The gap between the two drugs in your pharmacy is 18 months or more.

Who should actually wait for retatrutide?

A narrow group has a real case for waiting. If you are actively enrolled in a TRIUMPH trial, retatrutide is already accessible. If your BMI is above 45, the additional efficacy at the extreme end of the scale matters more than for someone at a lower starting weight. And if you have documented tirzepatide intolerance, the side effect profile comparison becomes less relevant.

For most people, the math does not favor waiting. Eighteen months of untreated or under-treated obesity is not metabolically neutral. Tirzepatide produces 20.9% weight loss. That outcome, achieved now, improves cardiovascular risk, insulin resistance, joint load, and sleep quality. Waiting for 28.3% means deferring all of that.

Switching when retatrutide launches is an option that stays open. Starting now and switching later keeps both options alive. Starting nothing closes the first option permanently.

The bottom line on retatrutide vs tirzepatide

On the numbers, retatrutide wins. 28.3% vs 20.9% is the largest efficacy gap between any two approved or late-stage obesity drugs in clinical history. The glucagon receptor is doing real work that GIP and GLP-1 alone cannot replicate.

On the ground, tirzepatide wins for now. It is approved. It is available. It has years of safety data and millions of patients behind it. Retatrutide is, at best, 18 months away for people outside a clinical trial.

Read the full TRIUMPH-1 results breakdown for the osteoarthritis data, the BMI subgroup analyses, and what the dose escalation schedule actually looked like. And if you are trying to decide what to do now, see which programs are prescribing tirzepatide today.